Our Anti-HIV Jab will be Rolled out in 6 Weeks. But Funding Cuts Hollowed out the System Needed to Deliver it
Mitchell Warren, AVAC’s Executive Director warns: “We’re now building lenacapavir programmes on a foundation of sand, not stone”.
April 21, 2026 — Bhekisisa
The Big US Bet on HIV Prevention — And Why it Might Not Work
AVAC Executive Director Mitchell Warren warns that the 3 million goal isn’t enough, saying at least 5 million people must be using the drug in order to push down prices. And beyond that, he says, the destruction of USAID has destabilized HIV prevention programs across the world. “I worry we are building lenacapavir programs on a foundation of sand.”
April 15, 2026 — Devex
Is There Enough of this Game-changing HIV Prevention Drug?
As AVAC Executive Director Mitchell Warren put it: “This continues to be a moment of cruelest irony — our best opportunity in HIV prevention coming at the worst time politically and economically.”
April 8, 2026 — Healthbeat
Gilead Could Potentially End HIV. But Will It Be Able To?
“There’s a cruel irony right now. One of our greatest opportunities is coming at one of the most politically difficult times.” according to AVAC Executive Director Mitchell Warren.
March 20, 2026 – PharmaVoice
180,000 Infections in 2024, 47,000 by 2045 — If SA rolls out the twice-a-year HIV prevention jab fast enough
AVAC Executive Director, Mitchell Warren, says his hope for the coming year: “When history is written, we’ll look back to 2026 and say ‘South Africa did the right thing in its Aids response and it helped the world when Pepfar wouldn’t.'”
March 19, 2026 — Bhekisisa
CAB-LA: The prevention jab that never had its moment, and what it leaves behind as LEN arrives
“Cabotegravir was the front end of our learning about long-acting injectables,” says Mitchell Warren of AVAC. “People have been trained. Systems have been set up… It was an investment. It wasn’t a waste.”
March 16, 2026 — Bhekisisa
The Benefits To Americans Of US-Supported International HIV Research
The tools, protocols, and systems tested and refined in international settings improve care, prevention, and delivery of HIV services in the US.
March 13, 2026 — Health Affairs
Kenya Rolls Out Breakthrough HIV Drug. Now the Real Test Begins.
“PrEP has never been just a pill or an injection; its success is beyond buying the medicines,” said Mitchell Warren, AVAC Executive Director.
February 27, 2026 — Defrontera
Foreign Aid is Back from the Dead — But it’s in the Hands of the People who Tried to Kill it
“Congress abdicated their responsibility [last year] for ensuring that the president spent what they had appropriated,” said Mitchell Warren, head of AVAC. Whether this Congress will act differently is an open question.
February 27, 2026 — Vox
New HIV Drug May End Multi-pill Regimen for Older People
“That is an incredible opportunity to make it simple for people to adhere to their drugs, to stay virologically suppressed. And that’s not only good for their lives as someone living with HIV, but we know from data over the last 15 years that people on antiretroviral therapy, who are virally suppressed, are not going to transmit the virus to anyone else,” said Mitchell Warren, executive director the HIV prevention advocacy group AVAC.
February 26, 2026 — DW.com
What Will HIV Funding Look Like in 2026?
“It’s bad for the HIV response in South Africa and around the world, but it’s also just the most remarkably dumb economic policy, because South Africa is the strongest economy on the continent [and the goal of PEPFAR’s investment is to build a market for lenacapavir as fast as possible],” says Mitchell Warren, AVAC Executive Director, in conversation with Bhekisisa.
February 5, 2026 — Bhekisisa
US Retreat from WHO Harms Global Health and the HIV Response
Epidemics know no borders; the role of institutions like the World Health Organization is critical, writes AVAC’s Mitchell Warren.
February 2, 2026 — Positively Aware
One Year after US Aid Freeze, HIV Care in Africa is in Retreat
One year after President Donald Trump froze US foreign aid, HIV treatment still exists across much of Africa — but the outreach, prevention, and monitoring systems that sustained it are fraying.
January 26, 2026 – Devex
Fighting for Billions: The legal battle to keep US foreign aid alive
Frozen programs, delayed payments, and billions at stake. AVAC’s lawsuit testing the limits of US foreign aid continues, nearly one year after it began.
January 20, 2026 – Devex
One Year After Trump: The day HIV funding changed forever — and what came next
One year ago, Donald Trump was inaugurated as president of the United States and, overnight, US policies on HIV funding for countries like South Africa changed. Mia Malan speaks with AVAC Executive Director Mitchell Warren to find out how international aid has changed.
January 20, 2026 — Bhekisisa
‘Coercive’ Trump-led US Health Deals Could Cause Global Abortion Access to Collapse, Charities Warn
Leading NGOs fear the deals in Africa – offering financial assistance in exchange for things like mining rights and access to health data – are worded vaguely enough for the US to impose restrictions on reproductive rights.
January 16, 2026 — The Independent
Unexpected Global Health Wins in the US Foreign Aid Bill
“Almost a year since the US administration decimated the US Agency for International Development… Congress is coming back with a bill that rejects the administration’s shortsighted decisions last year,” Mitchell Warren, Executive Director of AVAC, told Devex.
January 14, 2026 — Devex
US Cuts to HIV Programs in Sub-Saharan Africa Pose Global Risk, Experts Say
“There are still 1.3 million new HIV infections every year, which means the pool of people who need treatment will grow rapidly without more prevention,” Mitchell Warren, AVAC Executive Director, said.
January 13, 2026 — CIDRAP
→ Continue through the archives. Find articles from 2025 and older.